Quantum Biopharma Class B Subordinate Voting Shares

QNTM

Market cap $16.1M

New class action for Quantum (QNTM) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 2/23/2026.

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. (“Quantum” or the “Company”) (NASDAQ: QNTM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

New class action for Quantum Biopharma Ltd urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 2/23/2026.

LOS ANGELES, Feb. 02, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Quantum Biopharma Ltd. (“Quantum” or the "Company") (NASDAQ: QNTM) investors of a class action on behalf of investors that bought securities between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”). Quantum investors have until February 23, 2026 to file a lead plaintiff motion.

New class action for Quantum Biopharma Ltd urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 2/23/2026.

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. ("Quantum" or the "Company") (NASDAQ: QNTM).

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. (“Quantum” or the “Company”) (NASDAQ: QNTM).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

New class action for Quantum Biopharma Ltd urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 2/23/2026.

New class action for Quantum Biopharma Ltd urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 2/23/2026.

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. ("Quantum" or the "Company") (NASDAQ: QNTM).